Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof

Patent metadata

Field	Value
Publication number	US-2018311310-A1
Application number	US-201815914925-A
Country	US
Kind code	A1
Filing date	Mar 7, 2018
Priority date	Mar 7, 2017
Publication date	Nov 1, 2018
Grant date	—

Abstract

Therapeutic compositions and an associated method for improving a Toll-like receptor (TLR)-related condition, including determining a set of peptide sequences associated with a microorganism-related modulator of a TLR, determining a first set of binding parameters for the set of peptide sequences in relation to the TLR, selecting a target subset of peptide sequences from the set of peptide sequences based on the first set of binding parameters, reengineering the target subset of peptide sequences based on mutating amino acid residues of the target subset of peptide sequences, determining a second set of binding parameters for the reengineered target subset of peptide sequences in relation to the TLR, and identifying a first peptide for use in a therapeutic composition for improving the TLR-related condition, based on the second set of binding parameters for the reengineered target subset of peptide sequences.

First claim

1 . A therapeutic composition for improving a Toll-like receptor (TLR)-related condition, the therapeutic composition comprising a peptide configured to modulate TLR-related functionality and derived based on reengineering of a target peptide sequence associated with a microorganism-related modulator of a TLR, wherein the peptide corresponds to a peptide sequence derivable from at least one motif of a set of peptide sequence motifs comprising:
a first motif comprising XXGFXLKXX (SEQ ID NO: 1), wherein X in the first motif comprises any amino acid type or no amino acid; a second motif comprising XXTPA[Z][B]XXX (SEQ ID NOS:2-5), wherein X in the second motif comprises any amino acid type or no amino acid, wherein Z in the second motif comprises at least one of (N,D), and wherein B in the second motif comprises at least one of (N,E); a third motif comprising [X][Z][B]APW (SEQ ID NOS:6-245), wherein X in the third motif comprises at least one of (I,F,W,Y,A), wherein Z in the third motif comprises at least one of (D,A,Q,E,G,H,I,L,F,P,T,Y), and wherein B in the third motif comprises at least one of (Q,L,W,Y); a fourth motif comprising PP[X][Z][B][O]P (SEQ ID NOS:246-693), wherein X in the fourth motif comprises at least one of (Y,P), wherein Z in the fourth motif comprises at least one of (W,Y,F,A,V,C,T,L,S,H,Q,E,G,I), wherein B in the fourth motif comprises at least one of (W,I,F,P,D,G,C,A), and wherein O in the fourth motif comprises at least one of (G,N); a fifth motif comprising [X][Z][i][O][B][J][f] (SEQ ID NOS: 694-35253), wherein X in the fifth motif comprises at least one of (G,Y,W), wherein Z in the fifth motif comprises at least one of (W,V,I,F,R,M,S,L), wherein i in the fifth motif comprises at least one of (I,G), wherein O in the fifth motif comprises at least one of (Y,P,H,L,F), wherein B in the fifth motif comprises at least one of (I,D,Y,F,V,T,G,A,Q), wherein J in the fifth motif comprises at least one of (F,R,C,L,A,Q,D,V), and wherein fin the fifth motif comprises at least one of (F,Y); a sixth motif comprising F[X]PPAP[J] (SEQ ID NOS:35254-35269), wherein X in the sixth motif comprises at least one of (P,S), and wherein J in the sixth motif comprises at least one of (P,Y,L,A,E,G,V,I); a seventh motif comprising DFT[X]FPP (SEQ ID NOS:35270-35271), wherein X in the seventh motif comprises at least one of (V,I); an eighth motif comprising [X]TPA[J]F[B] (SEQ ID NOS:35272-35283), wherein X in the eight motif comprises at least one of (Y,T,H), wherein J in the eight motif comprises at least one of (H,I), and wherein B in the eight motif comprises at least one of (Y,A); a ninth motif comprising [B]AR[X]TP[Z]SPP (SEQ ID NOS:35284-35303), wherein B in the ninth motif comprises at least one of (P,A), wherein X in the ninth motif comprises at least one of (A,P,W,N,L), and wherein Z in the ninth motif comprises at least one of (P,F); a tenth motif comprising [X][J]TAYKP[B] (SEQ ID NOS:35304-35323), wherein X in the tenth motif comprises at least one of (W,L), wherein J in the tenth motif comprises at least one of (A,N,S,W,E), and wherein B in the tenth motif comprises at least one of (S,F); an eleventh motif comprising [X]A[J][B]AP[Z]I[O][U] (SEQ ID NOS:35324-35803), wherein X in the eleventh motif comprises at least one of (N,W,A), wherein J in the eleventh motif comprises at least one of (F,N,Y,P), wherein B in the eleventh motif comprises at least one of (P,H,Y,W,A), wherein Z in the eleventh motif comprises at least one of (Y,A), wherein O in the eleventh motif comprises at least one of (W,Q), and wherein U in the eleventh motif comprises at least one of (R, Q); and a twelfth motif comprising H[X][J]QP[B]AQEP (SEQ ID NOS:35804-35839), wherein X in the twelfth motif comprises at least one of (E,G,W,F), wherein J in the twelfth motif comprises at least one of (G,A,N), and wherein B in the twelfth motif comprises at least one of (H,W,K).

2 . The therapeutic composition of claim 1 , wherein the peptide is derived based on reengineering of the target peptide sequence associated with the microorganism-related modulator associated with Amuc_1100 protein from Akkermansia muciniphila , and wherein the peptide corresponds to the peptide sequence derivable from the at least one motif comprising at least one of the first motif, the second motif, the third motif, the fourth motif, the fifth motif, the tenth motif, the eleventh motif, and the twelfth motif.

3 . The therapeutic composition of claim 2 , wherein the peptide is derived based on reengineering of the target peptide sequence associated with the microorganism-related modulator associated with Amuc_1100 and on a binding parameter value for the peptide for a TLR binding site for Staphylococcal Superantigen-Like protein 3 (SSL3), and wherein the peptide corresponds to the peptide sequence derivable from the at least one motif comprising at least one of the third motif, the fourth motif, and the fifth motif.

4 . The therapeutic composition of claim 2 , wherein the peptide is derived based on reengineering of the target peptide sequence associated with the microorganism-related modulator associated with Amuc_1100 and on a binding parameter value for the peptide for a TLR binding site for a proline-proline glutamic acid protein, and wherein the peptide corresponds to the peptide sequence derivable from the at least one motif comprising at least one of the tenth motif, the eleventh motif, and the twelfth motif.

5 . The therapeutic composition of claim 1 , wherein the peptide is derived based on reengineering of the target peptide sequence associated with the microorganism-related modulator associated with Rv1168c protein from Mycobacterium tuberculosis , and wherein the peptide corresponds to the peptide sequence derivable from the at least one motif comprising at least one of the sixth motif, the seventh motif, the eighth motif, and the ninth motif.

6 . The therapeutic composition of claim 5 , wherein the peptide is derived based on reengineering of the target peptide sequence associated with the microorganism-related modulator associated with Rv1168c and on a binding parameter value for the peptide for a TLR binding site for Staphylococcal Superantigen-Like protein 3 (SSL3), and wherein the peptide corresponds to the peptide sequence derivable from the at least one motif comprising at least one of the sixth motif, the seventh motif, and the eighth motif.

7 . The therapeutic composition of claim 5 , wherein the peptide is derived based on reengineering of the target peptide sequence associated with the microorganism-related modulator associated with Rv1168c and on a binding parameter value for the peptide for a TLR binding site for a proline-proline glutamic acid protein, and wherein the peptide corresponds to the peptide sequence derivable from the at least one motif comprising the ninth motif.

8 . The therapeutic composition of claim 1 , wherein the peptide is configured to modulate TLR2-related functionality and derived based on reengineering of the target peptide sequence associated with a microorganism-related modulator of TLR2, and wherein the TLR-related condition comprises at least one of a metabolic disease and an immune disorder.

9 . The therapeutic composition of claim 1 , wherein the peptide corresponds to the peptide sequence with at least 90% identity to a determined peptide sequence derivable from the at least one motif of the set of peptide sequence motifs.

10 . The therapeutic composition of claim 1 , wherein the peptide is derived based on reengineering of the target peptide sequence associated with the microorganism-related modulator associated with a set of taxa comprising at least one of: Akkermansia muciniphila, Mycobacterium tuberculosis, Faecalibacteri

Assignees

• Ubiome Inc

Inventors

• Apte Zachary
• Richman Jessica
• Almonacid Daniel
• Alegria Melissa
• Marquez Valeria
• Morales Eduardo
• Ortiz Rodrigo
• Torres Janet
• Covarrubias Paulo
• Gimpel Javier
• Araya Ingrid

Classifications

• A61K38/164 Primary

  from bacteria · CPC title

• A61K38/08

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• C07K14/001

  by chemical synthesis · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• G01N33/68

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title